Kristina Jonjev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kristina Jonjev has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandar M. Milosavljevic
Clinic of Cardiovascular Surgery, Institute for Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia
2 shared publications - Mirko Todić
Clinic of Cardiovascular Surgery, Institute for Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia
2 shared publications - Živojin S. Jonjev
Clinic of Cardiovascular Surgery, Institute for Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia
2 shared publications - Anđela Božić
Institute for Cardiovascular Diseases of Vojvodina, Clinic of Cardiovascular Surgery, 21204 Sremska Kamenica, Serbia
1 shared publication - Ilija Bjeljac1 shared publication
Jovan Rajić
Clinic of Cardiovascular Surgery, Institute for Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia
1 shared publication
Latest Publications
- Open Access
- 28 April 2026
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 27, e951886
Prosthesis-Free Repair of Partial Atrioventricular Septal Defect in Down Syndrome: A Valve-Sparing Technique
Prosthesis-Free Repair of Partial Atrioventricular Septal Defect in Down Syndrome: A Valve-Sparing Technique - Article abstract #951886
- 28 April 2026
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 27, e951886
Open AccessProsthesis-Free Repair of Partial Atrioventricular Septal Defect in Down Syndrome: A Valve-Sparing Technique
Prosthesis-Free Repair of Partial Atrioventricular Septal Defect in Down Syndrome: A Valve-Sparing Technique - Article abstract #951886
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 2026 (1)
Ventricular Reverse Remodeling After Coronary Artery Bypass, Chordal‐Sparing Mitral Valve Replacement, and Tricuspid Valve Repair
Objective: This study aimed to evaluate the long‐term efficacy of a standardized triple procedure—coronary artery bypass grafting (CABG), chordal‐sparing mitral valve replacement, and tricuspid annuloplasty—in high‐risk patients with end‐stage ischemic dilated cardiomyopathy (IsDCM) for whom heart transplantation was not an option. Primary endpoints were survival, reverse ventricular remodeling, and functional recovery. Methods: We prospectively analyzed 42 consecutive patients (mean age 64.7 ± 9.1 years; 85.7% male) with end‐stage IsDCM. All presented with severe secondary mitral and tricuspid regurgitation, left ventricular ejection fraction (LVEF) < 30% (mean 26.4% ± 3.1%), left ventricular end‐diastolic diameter > 7.0 cm (mean 7.3 ± 0.3 cm), and coaptation depth > 1.0 cm. Mean STS‐predicted mortality risk was 22.0% ± 1.5%, and mean EuroSCORE II was 7.0% ± 1.0%. Results: Thirty‐day operative mortality was 2.4% ( n = 1). Significant reverse remodeling occurred: LVEF improved from 26.4% ± 3.1% to 34.6% ± 4.2% ( p < 0.001), and end‐systolic sphericity index decreased from 86.1% to 66.3%. NYHA class improved from 3.5 ± 0.5 to 1.8 ± 0.6 among survivors at 1 year ( p < 0.001). Long‐term survival was 78.5% ± 4.0% at 5 years and 54.8% ± 5.2% at 10 years. Conclusions: In high‐risk end‐stage IsDCM patients, CABG with chordal‐sparing mitral valve replacement and tricuspid annuloplasty facilitates substantial reverse remodeling, durable functional improvement, and excellent long‐term survival. This anatomy‐preserving strategy offers a viable alternative to transplantation or destination therapy for selected patients with advanced heart failure.
- 1 January 2026
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 2026 (1)
Open AccessVentricular Reverse Remodeling After Coronary Artery Bypass, Chordal‐Sparing Mitral Valve Replacement, and Tricuspid Valve Repair
Objective: This study aimed to evaluate the long‐term efficacy of a standardized triple procedure—coronary artery bypass grafting (CABG), chordal‐sparing mitral valve replacement, and tricuspid annuloplasty—in high‐risk patients with end‐stage ischemic dilated cardiomyopathy (IsDCM) for whom heart transplantation was not an option. Primary endpoints were survival, reverse ventricular remodeling, and functional recovery. Methods: We prospectively analyzed 42 consecutive patients (mean age 64.7 ± 9.1 years; 85.7% male) with end‐stage IsDCM. All presented with severe secondary mitral and tricuspid regurgitation, left ventricular ejection fraction (LVEF) < 30% (mean 26.4% ± 3.1%), left ventricular end‐diastolic diameter > 7.0 cm (mean 7.3 ± 0.3 cm), and coaptation depth > 1.0 cm. Mean STS‐predicted mortality risk was 22.0% ± 1.5%, and mean EuroSCORE II was 7.0% ± 1.0%. Results: Thirty‐day operative mortality was 2.4% ( n = 1). Significant reverse remodeling occurred: LVEF improved from 26.4% ± 3.1% to 34.6% ± 4.2% ( p < 0.001), and end‐systolic sphericity index decreased from 86.1% to 66.3%. NYHA class improved from 3.5 ± 0.5 to 1.8 ± 0.6 among survivors at 1 year ( p < 0.001). Long‐term survival was 78.5% ± 4.0% at 5 years and 54.8% ± 5.2% at 10 years. Conclusions: In high‐risk end‐stage IsDCM patients, CABG with chordal‐sparing mitral valve replacement and tricuspid annuloplasty facilitates substantial reverse remodeling, durable functional improvement, and excellent long‐term survival. This anatomy‐preserving strategy offers a viable alternative to transplantation or destination therapy for selected patients with advanced heart failure.